IBIO Archives - Page 2 of 6

Developments

Omicron variant underscores need for new COVID vaccine candidates like IBIO-202

iBio (NYSE American:IBIO) provided an updated on its lead COVID-19 vaccine program, IBIO-202, in light of the emergence of the Omicron variant of SARS-CoV-2. According to the WHO, the Omicron variant has at...

November 29, 2021

Developments

iBio, UT Southwestern to investigate IBIO-100 in solid tumors

iBio (NYSEA:IBIO) and the University of Texas Southwestern Medical Center entered into a research collaboration to explore in solid tumors the anti-cancer potential of the molecule that is part of the IBIO-100 program...

November 15, 2021

Developments

iBio acquires FastPharming manufacturing facility

iBio (NYSEA:IBIO) purchased the manufacturing facility it previously operated under a lease from two affiliates of Eastern Capital and also acquired the approximate 30% equity interest in iBio CDMO held by the...

November 4, 2021

Executive Moves

iBio names biotech veteran Chip Clark to the board

William (Chip) Clark iBio (NYSE:IBIO) appointed William (Chip) Clark to the board, effective immediately. Mr. Clark has more than 30 years of biotechnology and pharmaceutical experience, with a focus on business...

August 26, 2021

Developments

iBio acquires exclusive rights to develop anti-CD25 antibody RTX-003 from RubrYc

iBio (NYSEA:IBIO) bolstered its immuno-oncology pipeline with the acquisition of exclusive rights to develop and commercialize the anti-CD25 monoclonal antibody, RTX-003, from RubrYc. The partnership also includes an...

August 25, 2021

Developments

iBio featured in Genetic Engineering & Biotechnology News

The advantages of iBio’s (NYSE American:IBIO) plant-based drug production system was featured in the Aug. 4 edition of Genetic Engineering & Biotechnology News. The article quoted Randy Maddux, COO of iBio, who...

August 5, 2021

Developments

iBio posts positive preclinical immunization studies with next gen COVID-19 vaccine candidate

iBio (NYSE American:IBIO) announced that preclinical studies of IBIO-202, its subunit vaccine candidate that targets the nucleocapsid (N) protein of SARS-CoV-2, demonstrated a robust, antigen-specific, memory T...

July 16, 2021

Developments

iBio establishes oncology drug discovery pipeline with 3 new antibody programs

In a major step towards leveraging the speed and throughput of its proprietary, plant-based FastPharming protein expression system, iBio (NYSE American:IBIO) is adding three anti-cancer targets to its pipeline of...

July 9, 2021

Executive Moves

iBio adds veteran biopharmaceutical executive Evert Schimmelpennink to board

Evert Schimmelpennink iBio (NYSEA:IBIO) appointed Evert (Eef) Schimmelpennink to its board of directors, effective immediately. In an executive leadership career spanning more than 20 years, Mr. Schimmelpennink has...

June 10, 2021

Developments

iBio posts positive COVID-19 vaccine toxicology study results; announces next-generation COVID-19 vaccine program

iBio (NYSE American:IBIO) updated its IBIO-201 program and reported progress in developing a second-generation subunit vaccine candidate, IBIO-202, being designed for the prevention of SARS-CoV-2 infection. IBIO-201...

May 7, 2021

Tag - IBIO

Omicron variant underscores need for new COVID vaccine candidates like IBIO-202

iBio, UT Southwestern to investigate IBIO-100 in solid tumors

iBio acquires FastPharming manufacturing facility

iBio names biotech veteran Chip Clark to the board

iBio acquires exclusive rights to develop anti-CD25 antibody RTX-003 from RubrYc

iBio featured in Genetic Engineering & Biotechnology News

iBio posts positive preclinical immunization studies with next gen COVID-19 vaccine candidate

iBio establishes oncology drug discovery pipeline with 3 new antibody programs

iBio adds veteran biopharmaceutical executive Evert Schimmelpennink to board

iBio posts positive COVID-19 vaccine toxicology study results; announces next-generation COVID-19 vaccine program

General

More